President & Ceo
CurrentDeveloped program of client servicesFocus on all aspects of drug discovery chemistry Hypothesis-driven R&D strategy designed for target Hit-to-lead, lead optimization cycles Modeling, structure-based drug design, SAR All therapeutic areas and compound typesSpecial expertise in small molecule drug design, peptide therapeutics, and peptide mimeticsProject management and coordination of network resourcesBuilt Internal R&D programs and pipelineMHC Class II Inhibitors for Autoimmune Disease MS: PV-267 (development candidate) Lead series for RA, R&D for celiac and type 1 diabetesOncology (Chk2 kinase)Infectious disease (RNAP)